Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GCWB110 is an immune-enhancing probiotic candidate developed by GC Green Cross Wellbeing (GC Wellbeing). It is designed to enhance immune function by activating macrophage phagocytosis, restoring body weight and immune organ weight loss in immunosuppressed animal models, increasing immune-mediated cytokines, promoting immune cell proliferation, and activating natural killer (NK) cells. GCWB110 is being developed as an individually recognized health functional food ingredient in South Korea, with human clinical trials underway to evaluate its efficacy and safety.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GCWB110.